Rubicon Organics (ROMJ) Panoramica del titolo
Rubicon Organics Inc. e le sue consociate sono impegnate nella produzione, lavorazione e vendita di cannabis biologica per il mercato ricreativo e per uso medico in Canada e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
ROMJ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Rubicon Organics Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | CA$0.44 |
| Massimo di 52 settimane | CA$0.73 |
| Minimo di 52 settimane | CA$0.37 |
| Beta | 0.38 |
| Variazione di 1 mese | -2.22% |
| Variazione a 3 mesi | 0% |
| Variazione di 1 anno | -18.52% |
| Variazione a 3 anni | -12.00% |
| Variazione a 5 anni | -79.72% |
| Variazione dall'IPO | -86.46% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento narrativa • Mar 13
ROMJ: Cascadia Harvest Ramp Will Support Future Premium Capacity Upside
Analysts kept their fair value estimate for Rubicon Organics steady at CA$1.15, citing unchanged views on the discount rate, revenue growth expectations, profit margin assumptions and long term P/E outlook. What's in the News Rubicon Organics completed the first harvest of cannabis from its new Cascadia facility in Hope, British Columbia, following its acquisition in June 2025 (Key Developments).Aggiornamento narrativa • Feb 26
ROMJ: Cascadia Facility Ramp Up Will Support Future Premium Capacity Expansion
Analysts have kept their CA$1.15 price target on Rubicon Organics unchanged, citing essentially flat fair value, discount rate, revenue growth, profit margin, and a very high future P/E estimate that remains in place even after the latest refresh of their assumptions. What's in the News Rubicon Organics completed the first harvest of cannabis at its new Cascadia facility in Hope, British Columbia, after acquiring the site in June 2025 and preparing it for commercial production through capital investment and licensing work (Key Developments).Aggiornamento narrativa • Feb 11
ROMJ: New Permanent CFO Will Support Future Premium Capacity Expansion
Analysts have maintained their fair value estimate for Rubicon Organics at CA$1.15, indicating only very small adjustments to the discount rate, margin, and long-term P/E assumptions rather than any material change in their overall view. What's in the News Rubicon Organics appointed Glen Ibbott as Chief Financial Officer, formalizing his role after serving as interim CFO for about six months (Key Developments).Aggiornamento narrativa • Jan 27
ROMJ: New Permanent CFO Will Support Premium Capacity Expansion
The analyst price target for Rubicon Organics is unchanged at $1.15, as analysts see only minimal tweaks to inputs such as discount rate, revenue growth and profit margin that do not meaningfully alter their overall view of the shares. What's in the News Rubicon Organics appointed Glen Ibbott as Chief Financial Officer, following a six month period in which he served as interim CFO (Key Developments).Aggiornamento narrativa • Jan 11
ROMJ: New CFO And Cascadia License Will Support Premium Capacity Expansion
Analysts maintained their price target for Rubicon Organics at $1.15, citing only minor adjustments in their underlying assumptions for discount rate, revenue growth, profit margin and future P/E as the reason for no material change in their valuation view. What's in the News Rubicon Organics appointed Glen Ibbott, a veteran cannabis and life sciences finance executive and former CFO of Aurora Cannabis, as its Chief Financial Officer after serving as interim CFO for six months (Key Developments).Aggiornamento narrativa • Dec 25
ROMJ: New Licensed Facility Will Drive Premium Capacity Expansion By 2026
Analysts have maintained their price target on Rubicon Organics at approximately $1.15 per share, reflecting largely unchanged assumptions for revenue growth, profitability, and valuation multiples in their updated models. What's in the News Rubicon Organics appointed industry veteran Glen Ibbott, former CFO of Aurora Cannabis, as its new Chief Financial Officer after serving six months in an interim role, bringing over 25 years of public-company finance and cannabis sector experience (Key Developments).Aggiornamento narrativa • Dec 11
ROMJ: New Facility Expansion Will Support Premium Cannabis Output Growth By 2026
Analysts have maintained their price target for Rubicon Organics at 1.15 dollars, reflecting largely unchanged assumptions for growth, profitability, and valuation multiples in their updated models. What's in the News Rubicon Organics appointed Glen Ibbott, former Aurora Cannabis CFO with over 25 years of life sciences and cannabis finance leadership, as its new Chief Financial Officer after serving six months in an interim capacity (Key Developments).Aggiornamento narrativa • Nov 27
ROMJ: Cascadia Facility Expansion Will Increase Output by 40% by 2026
Analysts have reaffirmed Rubicon Organics' fair value estimate at $1.15, citing increased revenue growth projections that are balanced by a significant reduction in profit margin expectations. This combination has resulted in minimal change to the overall price target.Aggiornamento narrativa • Nov 13
ROMJ: Cascadia Facility Expansion Will Drive 40% Output Increase By 2026
Analysts maintained their price target for Rubicon Organics at $1.15. This reflects stable expectations, despite minor adjustments to sector discount rates and growth assumptions.Articolo di analisi • Nov 02
We Think Rubicon Organics (CVE:ROMJ) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aggiornamento narrativa • Oct 29
New Facility Will Drive 40% Capacity Increase And Long-Term Upside
Narrative Update on Rubicon Organics Analysts have maintained their fair value price target for Rubicon Organics at $1.15. Recent reassessments indicate minimal changes to underlying growth and profitability assumptions.Aggiornamento narrativa • Oct 15
Global Cannabis Acceptance And Facility Expansion Will Unlock Long-Term Opportunity
Analysts have revised their price target for Rubicon Organics downward by $0.15 to $1.15 per share, citing tempered revenue growth expectations. This adjustment comes despite a modest improvement in projected profit margins and a lower future price-to-earnings ratio.Aggiornamento narrativa • Aug 19
International Certifications And Capacity Expansion Will Unlock Premium Cannabis Markets
Driven by notable improvements in both forecasted revenue growth (from 10.6% to 16.3% annually) and net profit margin (from 2.67% to 4.92%), Rubicon Organics' consensus analyst price target has been raised from CA$1.10 to CA$1.30. What's in the News Rubicon Organics launched its new 1964 Supply Co. All-in-One Full Spectrum Extract Resin Vapes in Canada, featuring premium resin and targeting legacy market consumers; two more AIO products are planned by year-end.Articolo di analisi • Aug 06
Rubicon Organics Inc.'s (CVE:ROMJ) Price Is Out Of Tune With Revenues
TSXV:ROMJ 1 Year Share Price vs Fair Value Explore Rubicon Organics's Fair Values from the Community and select yours...Nuova narrativa • Jun 01
International Certifications And Capacity Expansion Will Unlock Premium Cannabis Markets
Certifications, facility expansion, and new exports position Rubicon Organics for broader international growth, revenue diversification, and increased premium product supply.Articolo di analisi • Mar 22
Investors Still Aren't Entirely Convinced By Rubicon Organics Inc.'s (CVE:ROMJ) Revenues Despite 37% Price Jump
Rubicon Organics Inc. ( CVE:ROMJ ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • Mar 14
Is Rubicon Organics (CVE:ROMJ) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Feb 05
Slammed 30% Rubicon Organics Inc. (CVE:ROMJ) Screens Well Here But There Might Be A Catch
Rubicon Organics Inc. ( CVE:ROMJ ) shareholders won't be pleased to see that the share price has had a very rough...Articolo di analisi • Dec 22
A Piece Of The Puzzle Missing From Rubicon Organics Inc.'s (CVE:ROMJ) 26% Share Price Climb
Rubicon Organics Inc. ( CVE:ROMJ ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • Sep 25
Health Check: How Prudently Does Rubicon Organics (CVE:ROMJ) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jun 08
Rubicon Organics Inc. (CVE:ROMJ) Soars 27% But It's A Story Of Risk Vs Reward
Rubicon Organics Inc. ( CVE:ROMJ ) shares have had a really impressive month, gaining 27% after a shaky period...Articolo di analisi • May 06
Calculating The Fair Value Of Rubicon Organics Inc. (CVE:ROMJ)
Key Insights Rubicon Organics' estimated fair value is CA$0.32 based on 2 Stage Free Cash Flow to Equity Current share...Articolo di analisi • Mar 07
Is Rubicon Organics (CVE:ROMJ) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Sep 28
Is Rubicon Organics (CVE:ROMJ) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 13
Benign Growth For Rubicon Organics Inc. (CVE:ROMJ) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Rubicon Organics Inc. ( CVE:ROMJ ) shares are down a considerable 26% in the...Articolo di analisi • Jun 06
Is Rubicon Organics (CVE:ROMJ) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendimenti per gli azionisti
| ROMJ | CA Pharmaceuticals | CA Mercato | |
|---|---|---|---|
| 7D | -20.0% | -1.5% | 1.0% |
| 1Y | -18.5% | -1.3% | 31.3% |
Ritorno vs Industria: ROMJ ha avuto una performance inferiore rispetto al Canadian Pharmaceuticals che ha registrato un rendimento -1.3 % nell'ultimo anno.
Rendimento vs Mercato: ROMJ ha avuto una performance inferiore al mercato Canadian che ha registrato un rendimento 31.3 % nell'ultimo anno.
Volatilità dei prezzi
| ROMJ volatility | |
|---|---|
| ROMJ Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 16.4% |
| 10% least volatile stocks in CA Market | 3.8% |
Prezzo delle azioni stabile: ROMJ non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Canadian.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di ROMJ è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2015 | 265 | Margaret Brodie | www.rubiconorganics.com |
Rubicon Organics Inc. e le sue consociate sono impegnate nella produzione, lavorazione e vendita di cannabis biologica per il mercato ricreativo e per uso medico in Canada e a livello internazionale. L'azienda offre prodotti a base di cannabis in barattolo, sacchetto, pre-roll, commestibili, mix di salsa poutine, fiori macinati, soft gel, hashish, blunt, gummies, confezione di varietà di fiori, brownie di erba, vape di resina, stick di sollievo, stick fresco e olio. Vende i suoi prodotti con i marchi Simply Bare Organic, 1964 Supply Co, Homestead Cannabis Supply, LAB THEORY e Wildflower.
Rubicon Organics Inc. Riepilogo dei fondamenti
| ROMJ statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | CA$31.09m |
| Utili (TTM) | -CA$1.74m |
| Ricavi(TTM) | CA$64.23m |
0.5x
Rapporto P/S-17.1x
Rapporto P/EROMJ è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ROMJ Conto economico (TTM) | |
|---|---|
| Ricavi | CA$64.23m |
| Costo del fatturato | CA$41.11m |
| Profitto lordo | CA$23.12m |
| Altre spese | CA$24.86m |
| Utili | -CA$1.74m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.026 |
| Margine lordo | 35.99% |
| Margine di profitto netto | -2.71% |
| Rapporto debito/patrimonio netto | 33.3% |
Come si è comportato ROMJ nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/14 08:14 |
| Prezzo dell'azione a fine giornata | 2026/08/14 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Rubicon Organics Inc. è coperta da 7 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Nicholas Cortellucci | Atrium Research |
| Ben Pirie | Atrium Research |
| Kimberly Thompson-Hedlin | Canaccord Genuity |